Fennec Pharmaceuticals Inc. (FENC) Q2 2025 Earnings Call Transcript

Fennec Pharmaceuticals Inc. reported robust Q2 2025 net product sales of $9.7 million, marking a 33% year-over-year and 10% sequential increase, representing the third consecutive quarter of growth for PEDMARK. This momentum is attributed to increased awareness and adoption, including the addition of PEDMARK to a large national oncology group's formulary and a positive quality intervention (PQI) from NCODA, alongside 14 new account activations. The company anticipates accelerated growth in the second half of 2025 as commercial initiatives mature and cash operating expenses are expected to decrease, while also highlighting early traction from its EU partnership with Norgine and potential monetization opportunities from Q4 2025 Japan study results.

Analysis

Fennec Pharmaceuticals reported strong Q2 2025 results, demonstrating continued commercial execution for its sole product, PEDMARK. Net product sales reached $9.7 million, reflecting a 33% year-over-year and 10% sequential increase, marking the third consecutive quarter of growth. This performance is directly attributed to a revamped go-to-market strategy, which has resulted in tangible wins, including the activation of 14 new accounts and the addition of PEDMARK to the formulary of a large national community oncology group for patients under 40. Further supporting its primary goal of establishing PEDMARK as the standard of care, the company secured a positive quality intervention (PQI) from NCODA, providing practical, peer-reviewed guidance for its use in the key pediatric and adolescent and young adult (AYA) populations. Management projects that the most significant growth will occur in the second half of 2025, supported by maturing commercial initiatives and a planned decrease in cash operating expenses from the front-loaded levels seen in the first half. The company ended the quarter with $18.7 million in cash after a $4 million cash burn. Looking ahead, key catalysts include the European rollout by partner Norgine, which is showing early traction and carries potential royalty and milestone payments, and the expected Q4 2025 results from a Japanese study, which could unlock a new market through partnership or monetization.

Key Decisions for Investors

• Investors should closely monitor revenue in the second half of 2025 to validate management's guidance for accelerated growth, as this is critical for the company to achieve its aim of cash profitability.
• The pace of new account adoption and evidence of deeper penetration within existing accounts are key metrics to watch, as they will signal the success of PEDMARK's uptake in the significantly larger adolescent and young adult (AYA) market.
• Upcoming catalysts to monitor include news on final German pricing for PEDMARQSI, which could trigger a milestone payment from Norgine, and the release of Japanese study results in Q4, which presents a significant monetization opportunity.
• Given the $18.7 million cash balance and a quarterly burn rate of approximately $4 million, the company's ability to successfully scale revenue while reducing operating expenses in the coming quarters is crucial to extending its financial runway.